4//SEC Filing
Castellanos Elaine 4
Accession 0001209191-21-039175
CIK 0001358762other
Filed
Jun 8, 8:00 PM ET
Accepted
Jun 9, 4:28 PM ET
Size
27.9 KB
Accession
0001209191-21-039175
Insider Transaction Report
Form 4
Castellanos Elaine
See Remarks
Transactions
- Conversion
Class A common stock
2021-06-07+1,546→ 16,092 total - Sale
Class A common stock
2021-06-09$141.86/sh−7,900$1,120,688→ 15,100 total - Conversion
Class B common stock
2021-06-07−1,546→ 0 total→ Class A common stock (1,546 underlying) - Exercise/Conversion
Class B common stock
2021-06-09$22.57/sh+8,454$190,807→ 8,454 total→ Class A common stock (8,454 underlying) - Sale
Class A common stock
2021-06-09$142.50/sh−554$78,943→ 14,546 total - Exercise/Conversion
Class B common stock
2021-06-07$22.57/sh+1,546$34,893→ 1,546 total→ Class A common stock (1,546 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2021-06-09−8,454→ 9,934 totalExercise: $22.57Exp: 2026-12-07→ Class B common stock (8,454 underlying) - Conversion
Class B common stock
2021-06-09−8,454→ 0 total→ Class A common stock (8,454 underlying) - Sale
Class A common stock
2021-06-07$146.47/sh−910$133,287→ 15,182 total - Conversion
Class A common stock
2021-06-09+8,454→ 23,000 total - Exercise/Conversion
Employee Stock Option (right to buy)
2021-06-07−1,546→ 18,388 totalExercise: $22.57Exp: 2026-12-07→ Class B common stock (1,546 underlying) - Sale
Class A common stock
2021-06-07$147.16/sh−636$93,595→ 14,546 total
Footnotes (6)
- [F1]The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $146.05 to $146.94. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $147.09 to $147.255. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $141.25 to $142.07. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions on one day at prices ranging from $142.43 to $142.71. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
- [F6]The options vest in twenty equal quarterly installments beginning on March 7, 2017, subject to continued service through each vesting date.
Documents
Issuer
REATA PHARMACEUTICALS INC
CIK 0001358762
Entity typeother
Related Parties
1- filerCIK 0001662520
Filing Metadata
- Form type
- 4
- Filed
- Jun 8, 8:00 PM ET
- Accepted
- Jun 9, 4:28 PM ET
- Size
- 27.9 KB